Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARANASDAQ:HURANASDAQ:IOBTNASDAQ:OPTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4123,208 shs237,144 shsHURATuHURA Biosciences$2.40-3.2%$3.10$1.80▼$7.93$104.83M0.17264,306 shs207,059 shsIOBTIO Biotech$1.43-4.0%$1.27$0.66▼$1.73$94.21M0.36283,908 shs209,959 shsOPTNOptiNose$9.60$9.55$4.82▼$19.50$97.22M-0.8862,916 shsN/A10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%+12.00%+55.66%HURATuHURA Biosciences0.00%+11.26%-12.10%-32.14%+246,999,900.00%IOBTIO Biotech0.00%+4.51%-5.94%+65.38%+25.42%OPTNOptiNose0.00%0.00%0.00%+5.49%-38.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics0.3412 of 5 stars0.00.00.04.20.60.80.0HURATuHURA Biosciences1.227 of 5 stars3.70.00.00.00.90.00.0IOBTIO Biotech2.6363 of 5 stars3.73.00.00.00.62.50.6OPTNOptiNose0.7278 of 5 stars1.00.00.04.20.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/AHURATuHURA Biosciences 3.40Buy$12.67427.78% UpsideIOBTIO Biotech 3.33Buy$9.33552.68% UpsideOPTNOptiNose 2.00Hold$9.00-6.25% DownsideCurrent Analyst Ratings BreakdownLatest CARA, OPTN, HURA, and IOBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.005/16/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.005/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AOPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AHURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%N/AIOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)OPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)Latest CARA, OPTN, HURA, and IOBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/13/2025Q1 2025OPTNOptiNose-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71HURATuHURA BiosciencesN/A3.003.00IOBTIO BiotechN/A2.322.32OPTNOptiNoseN/A0.790.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%HURATuHURA Biosciences0.62%IOBTIO Biotech54.76%OPTNOptiNose85.60%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%HURATuHURA Biosciences0.20%IOBTIO Biotech2.30%OPTNOptiNose2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/AIOBTIO Biotech3065.88 million64.37 millionNot OptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableCARA, OPTN, HURA, and IOBT HeadlinesRecent News About These CompaniesParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty TherapiesMay 21, 2025 | finance.yahoo.comOptinose Stockholders Approve Merger with ParatekMay 16, 2025 | tipranks.comOptiNose (OPTN) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comOptiNose (OPTN) Reports Q4 Loss, Tops Revenue EstimatesMarch 26, 2025 | zacks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comMWall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to TradeMarch 24, 2025 | zacks.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNMarch 21, 2025 | businesswire.comOPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekMarch 21, 2025 | zacks.comOptinose downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comOptinose downgraded to Hold from Buy at Lake StreetMarch 21, 2025 | markets.businessinsider.comLake Street Downgrades OptiNose (OPTN)March 21, 2025 | msn.comWhy OptiNose Inc. (OPTN) Surged On Thursday?March 21, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersMarch 21, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | gurufocus.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, OPTN, HURA, and IOBT Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.TuHURA Biosciences NASDAQ:HURA$2.40 -0.08 (-3.23%) Closing price 04:00 PM EasternExtended Trading$2.40 0.00 (0.00%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.IO Biotech NASDAQ:IOBT$1.43 -0.06 (-4.03%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.06 (-4.55%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.OptiNose NASDAQ:OPTN$9.60 0.00 (0.00%) As of 05/21/2025OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
